Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

"Modular" PMAs.

This article was originally published in The Gray Sheet

Executive Summary

Up to three guidance documents explaining FDA's proposed policy for arranging modular premarket approval applications with device sponsors are expected to be released in April, agency staffers say. Guidances for the policy, which was outlined by FDA Office of Device Evaluation Director Susan Alpert at a Feb. 25 videoconference ("The Gray Sheet" March 2, p. 5), will explain what constitutes a PMA "shell" and the modules needed to complete it; methods for assembling the summary of safety and effectiveness data; and requirements for labeling and proper closure of the process, FDAers indicate...

You may also be interested in...



Global Pharma Guidance Tracker – November 2020

Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.

Execs On The Move: New CEOs At Alpha Source And Mölnlycke; Xvivo Perfusion CFO Gets New Title

Alpha Source hired a new CEO from Mayline, while Mölnlycke’s CEO comes from CellaVision; Xvivo Perfusion finance chief changed job to become chief operating officer; Shire senior VP now COO at AVITA; and more.

The Race To Develop A COVID-19 Vaccine: mRNA Pioneers Lead The Way

Our updated graphic tracker of key developments from the leading vaccine candidates.

UsernamePublicRestriction

Register

LL1134940

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel